<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386970</url>
  </required_header>
  <id_info>
    <org_study_id>04-1101</org_study_id>
    <secondary_id>R01AI064029</secondary_id>
    <nct_id>NCT01386970</nct_id>
  </id_info>
  <brief_title>Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics</brief_title>
  <official_title>Sex and Disease Dependent Nucleoside Analog Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in
      men versus women and in those with versus without HIV infection. Additionally, markers of
      side effects were correlated with blood levels of the drugs. The hypothesis was that women
      and those with HIV would have higher drug levels, as well as markers of side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</measure>
    <time_frame>Day 12 of dosing</time_frame>
    <description>To compare ZDV- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3TC-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</measure>
    <time_frame>Day 12 of dosing</time_frame>
    <description>To compare 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV-negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine 300mg and lamivudine 150mg as Combivir</intervention_name>
    <description>twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group</description>
    <arm_group_label>HIV-infected</arm_group_label>
    <arm_group_label>HIV-negative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+);
             HIV-negative volunteers must have a negative HIV-ELISA.

          -  Age 18 to 55 years;

          -  Either antiretroviral na√Øve, or no HIV-therapy in the preceding 6 months;

          -  Planned antiretroviral regimen includes standard doses of ZDV plus 3TC as part of the
             antiretroviral regimen. Once- or twice-daily 3TC will be allowed.

        Exclusion Criteria:

          -  Any medical condition that in the opinion of the investigators would jeopardize the
             intent of the study.

          -  In the opinion of the investigator, any concomitant immunomodulatory medications,
             chemotherapeutic agents, investigational drugs, and alternative therapies, including,
             glucocorticoids, recombinant growth factors or cytokines (e.g. Granulocyte-macrophage
             colony-stimulating factor, Granulocyte colony-stimulating factor, interferon-alpha or
             gamma, human growth hormone, etc), ribavirin, birth-control pills, and sex hormones
             that could interfere with the cellular pharmacology of the study medications;

          -  Concomitant medications that interfere with renal drug clearances including,
             tenofovir, adefovir, cidofovir, ganciclovir, probenecid, or any similarly problematic
             medication in the opinion of the investigators;

          -  Concomitant warfarin or daily aspirin (to prevent excess bleeding from biopsy).

          -  Pregnancy or a plan to become pregnant, or menopause;

          -  Any &gt; or = grade II abnormality in hemoglobin, absolute neutrophil count, routine
             liver function tests, serum creatinine, or other organ function abnormalities.

          -  Any medical or personal condition that, in the judgment of the investigators, may
             influence the subject's ability to comply with study conditions, such as active mental
             illnesses, or plans to leave the geographical area.

          -  Inability to give informed consent.

          -  Triple nucleoside analog reverse transcriptase regimens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter L. Anderson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver and Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver and Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS. 2008 May;3(3):258-65. doi: 10.1097/COH.0b013e3282f85dc1.</citation>
    <PMID>19372976</PMID>
  </reference>
  <reference>
    <citation>Anderson PL, Rower JE. Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther. 2010;2:a2004.</citation>
    <PMID>20953318</PMID>
  </reference>
  <reference>
    <citation>Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec;22(12):891-4. doi: 10.1097/FPC.0b013e32835879a8.</citation>
    <PMID>22960662</PMID>
  </reference>
  <results_reference>
    <citation>Rower JE, Klein B, Bushman LR, Anderson PL. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr. 2012 Jan;26(1):12-20. doi: 10.1002/bmc.1617. Epub 2011 Apr 4.</citation>
    <PMID>21465499</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007 Sep 12;21(14):1849-54.</citation>
    <PMID>17721092</PMID>
  </results_reference>
  <results_reference>
    <citation>Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012 Jun;56(6):3011-9. doi: 10.1128/AAC.06337-11. Epub 2012 Mar 5.</citation>
    <PMID>22391541</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <results_first_submitted>February 14, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>nucleoside analogs</keyword>
  <keyword>mitochondrial toxicity</keyword>
  <keyword>clinical pharmacology</keyword>
  <keyword>cellular pharmacology</keyword>
  <keyword>pharmacogenetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV-negative</title>
          <description>This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
zidovudine 300mg and lamivudine 150mg as Combivir: twice daily for 12 days in the HIV-negative group</description>
        </group>
        <group group_id="P2">
          <title>HIV-infected</title>
          <description>This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
zidovudine 300mg and lamivudine 150mg as Combivir: indefinitely for their care in the HIV-positive group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV-negative</title>
          <description>This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
zidovudine 300mg and lamivudine 150mg as Combivir: twice daily for 12 days in the HIV-negative group</description>
        </group>
        <group group_id="B2">
          <title>HIV-infected</title>
          <description>This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
zidovudine 300mg and lamivudine 150mg as Combivir: indefinitely for their care in the HIV-positive group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non- African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</title>
        <description>To compare ZDV- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
        <time_frame>Day 12 of dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-negative</title>
            <description>This group was used to compare intracellular ZDV-triphosphate concentrations to the HIV-infected group
zidovudine 300mg twice daily for 12 days in the HIV-negative group</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected</title>
            <description>This group was used to compare intracellular ZDV-triphosphate concentrations to the HIV-infected group
zidovudine 300mg twice daily for 12 days in the HIV-negative group</description>
          </group>
        </group_list>
        <measure>
          <title>ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</title>
          <description>To compare ZDV- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
          <units>pmol/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.89" lower_limit="28.82" upper_limit="42.96"/>
                    <measurement group_id="O2" value="29.7" lower_limit="22.09" upper_limit="45.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3TC-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</title>
        <description>To compare 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
        <time_frame>Day 12 of dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-negative</title>
            <description>This group was used to measure intracellular 3TC-triphosphate concentrations in those who are HIV-negative
lamivudine 150mg twice daily for 12 days in the HIV-negative group</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected</title>
            <description>This group was used to measure intracellular 3TC-triphosphate concentrations in those who are HIV-positive
lamivudine 150mg twice daily indefinitely for their care in the HIV-positive group</description>
          </group>
        </group_list>
        <measure>
          <title>3TC-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject</title>
          <description>To compare 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
          <units>pmol/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" lower_limit="6.02" upper_limit="8.05"/>
                    <measurement group_id="O2" value="5.3" lower_limit="4.37" upper_limit="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consenting to study exit (Day 12 or earlier).</time_frame>
      <desc>AEs were graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 - December 2004 (Clarification dated August 2009) (US Dept HHS, NIH, NIAID) Available from: https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV-negative</title>
          <description>This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
zidovudine 300mg and lamivudine 150mg as Combivir: twice daily for 12 days in the HIV-negative group</description>
        </group>
        <group group_id="E2">
          <title>HIV-infected</title>
          <description>This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
zidovudine 300mg and lamivudine 150mg as Combivir: indefinitely for their care in the HIV-positive group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab- Amylase</sub_title>
                <description>Increase in amylase</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, Vomiting, and/or Diarrhea</sub_title>
                <description>GI distress leading to subject withdrawal</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab- Bilirubin</sub_title>
                <description>bilirubin increase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abnormal Lab- albumin</sub_title>
                <description>Decrease in albumin</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abnormal Lab- Alanine Aminotransferase (ALT)</sub_title>
                <description>increase in Alanine Aminotransferase (ALT)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abnormal Lab- Aspartate transaminase (AST)</sub_title>
                <description>increase in Aspartate transaminase (AST)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Anderson</name_or_title>
      <organization>University of Colorado | Skaggs School of Pharmacy and Pharmaceutical Sciences</organization>
      <phone>3037246128</phone>
      <email>peter.anderson@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

